{"doi":"10.1093/cid/ciac284","title":"Initiating Intramuscular Depot Medroxyprogesterone Acetate Increases Frequencies of Th17-like Human Immunodeficiency Virus Target Cells in the Genital Tract of Women in South Africa: A Randomized Trial","abstract":"BACKGROUND: Cervicovaginal CD4+ T cells are preferential targets for human immunodeficiency virus (HIV) infection and have consequently been used as a proxy measure for HIV susceptibility. The ECHO randomized trial offered a unique opportunity to consider the association between contraceptives and Th17-like cells within a trial designed to evaluate HIV risk. In a mucosal substudy of the ECHO trial, we compared the impact of initiating intramuscular depot medroxyprogesterone acetate (DMPA-IM), copper-IUD, and the levonorgestrel (LNG) implant on cervical T cells. METHODS: Cervical cytobrushes from 58 women enrolled in the ECHO trial were collected at baseline and 1 month after contraceptive initiation. We phenotyped cervical T cells using multiparameter flow cytometry, characterized the vaginal microbiome using 16s sequencing, and determined proteomic signatures associated with Th17-like cells using mass spectrometry. RESULTS: Unlike the LNG implant or copper-IUD, DMPA-IM was associated with higher frequencies of cervical Th17-like cells within 1 month of initiation (P = .012), including a highly susceptible, activated population co-expressing CD38, CCR5, and α4β7 (P = .003). After 1 month, women using DMPA-IM also had more Th17-like cells than women using the Cu-IUD (P = .0002) or LNG implant (P = .04). Importantly, in women using DMPA-IM, proteomic signatures signifying enhanced mucosal barrier function were associated with the increased abundance of Th17-like cells. We also found that a non-Lactobacillus-dominant microbiome at baseline was associated with more Th17-like cells post-DMPA-IM (P = .03), although this did not influence barrier function. CONCLUSIONS: Our data suggest that DMPA-IM-driven accumulation of HIV-susceptible Th17-like cells might be counteracted by their role in maintaining mucosal barrier integrity. CLINICAL TRIALS REGISTRATION: NCT02550067.","journal":"Clinical Infectious Diseases","year":2022,"id":270310,"datarank":0.6307971816131932,"base_score":2.70805020110221,"endowment":2.70805020110221,"self_citation_contribution":0.40620753016533157,"citation_network_contribution":0.2245896514478617,"self_endowment_contribution":0.40620753016533157,"citer_contribution":0.2245896514478617,"corpus_percentile":null,"corpus_rank":null,"citation_count":14,"citer_count":9,"citers_with_citation_signal":7,"citers_with_endowment":7,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.95,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT02550067"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":934571,"name":"Tanko F Ramla","orcid":null,"position":1,"is_corresponding":false},{"id":307179,"name":"Shameem Z. Jaumdally","orcid":"0000-0003-0316-7087","position":2,"is_corresponding":false},{"id":315893,"name":"Laura Noël‐Romas","orcid":null,"position":3,"is_corresponding":false},{"id":934572,"name":"Hossaena Ayele","orcid":null,"position":4,"is_corresponding":false},{"id":339449,"name":"Bryan P. Brown","orcid":"0000-0002-4476-6150","position":5,"is_corresponding":false},{"id":307188,"name":"Hoyam Gamieldien","orcid":"0000-0002-8352-9705","position":6,"is_corresponding":false},{"id":934573,"name":"Rushil Harryparsad","orcid":null,"position":7,"is_corresponding":false},{"id":764343,"name":"Smritee Dabee","orcid":"0000-0002-8373-9593","position":8,"is_corresponding":false},{"id":385138,"name":"Gonasagrie Nair","orcid":"0000-0001-9005-2442","position":9,"is_corresponding":false},{"id":394447,"name":"Maricianah Onono","orcid":"0000-0001-6847-8762","position":10,"is_corresponding":false},{"id":459399,"name":"Thesla Palanee‐Phillips","orcid":"0000-0002-0052-5830","position":11,"is_corresponding":false},{"id":934574,"name":"Catilin W Scoville","orcid":null,"position":12,"is_corresponding":false},{"id":654207,"name":"Kate B. Heller","orcid":null,"position":13,"is_corresponding":false},{"id":299060,"name":"Jared M. Baeten","orcid":"0000-0001-8242-8438","position":14,"is_corresponding":false},{"id":232942,"name":"Steven E. Bosinger","orcid":"0000-0002-2116-5061","position":15,"is_corresponding":false},{"id":314054,"name":"Adam Burgener","orcid":"0000-0002-2303-5738","position":16,"is_corresponding":false},{"id":307189,"name":"Jo‐Ann S. Passmore","orcid":"0000-0002-1471-4245","position":17,"is_corresponding":false},{"id":307190,"name":"Heather B. Jaspan","orcid":"0000-0002-0745-6073","position":18,"is_corresponding":false},{"id":299053,"name":"Renee Heffron","orcid":"0000-0001-6039-0352","position":19,"is_corresponding":false},{"id":584840,"name":"Rubina Bunjun","orcid":"0000-0002-8471-163X","position":0,"is_corresponding":true}],"reference_count":40,"raw_metadata":null,"created_at":"2026-07-19T00:27:26.772098Z","pmid":"35941737","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}